Investor Overview

Corporate Profile

vTv Therapeutics LLC (vTv) is a clinical-stage pharmaceutical company focused on treating metabolic and inflammatory disorders to minimize their long-term complications and improve the lives of patients. Our mission is to advance clinical drug candidates discovered with our innovative technology into safe and effective medicines.

vTv has an innovative pipeline of first-in-class small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of metabolic and inflammatory disorders such as type 1 diabetes and psoriasis . The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality of vTv’s product candidate pipeline, scientific team, clinical trial execution and strategic collaborations have enabled it to become a leader in its novel therapeutic targets.

Presentations

Date Title
More >>

Recent News

Date Title
Toggle Summary vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually
HIGH POINT, N.C. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that it is participating in the LifeSci
View HTML
Toggle Summary vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes
HIGH POINT, N.C. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as
View HTML
Toggle Summary vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio
HIGH POINT, N.C. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compound, HPP971.
View HTML
Toggle Summary vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital
HIGH POINT, N.C. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $47 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago -based institutional investor.
View HTML
Webcasts
More >>
Upcoming Events
More events are coming soon.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.